Gert J Ossenkoppele
Overview
Explore the profile of Gert J Ossenkoppele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
216
Citations
10526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reuvekamp T, Ngai L, den Hartog D, Carbaat-Ham J, Fayed M, Scholten W, et al.
Leukemia
. 2025 Feb;
PMID: 40016301
No abstract available.
2.
Venditti A, Palmieri R, Maurillo L, Rollig C, Wierzbowska A, De Leeuw D, et al.
Blood Adv
. 2025 Feb;
PMID: 39913928
Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. While several scoring systems are available to aid in determining...
3.
Vonk C, Grob T, Rijken M, Kavelaars F, Konijnenburg J, Konijnenburg J, et al.
Blood Adv
. 2024 Dec;
9(5):1069-1077.
PMID: 39637308
Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable...
4.
Voso M, Guarnera L, Lehmann S, Lehmann S, Dohner K, Dohner H, et al.
Blood
. 2024 Nov;
145(2):234-243.
PMID: 39504485
Treatment outcomes for acute promyelocytic leukemia (APL) have improved with the widespread use of targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Our study aimed to validate...
5.
Huls G, Chitu D, Tick L, Boersma R, Breems D, Herbers A, et al.
Ann Hematol
. 2024 Oct;
104(1):361-368.
PMID: 39367118
The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor...
6.
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen N, et al.
J Clin Oncol
. 2024 Sep;
42(34):4084-4094.
PMID: 39231389
Purpose: AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive chemotherapy followed...
7.
Reuvekamp T, Janssen L, Ngai L, Carbaat-Ham J, den Hartog D, Scholten W, et al.
Cytometry B Clin Cytom
. 2024 Aug;
108(1):23-34.
PMID: 39177948
The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38- LSC...
8.
Rodriguez-Arboli E, Othus M, Freeman S, Buccisano F, Ngai L, Thomas I, et al.
Leukemia
. 2024 Aug;
38(10):2266-2269.
PMID: 39169114
No abstract available.
9.
van der Maas N, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, et al.
Blood Cancer J
. 2024 Mar;
14(1):56.
PMID: 38538587
Randomized controlled trials (RCTs) are the gold standard to establish the benefit-risk ratio of novel drugs. However, the evaluation of mature results often takes many years. We hypothesized that the...
10.
Tettero J, Heidinga M, Mocking T, Fransen G, Kelder A, Scholten W, et al.
Leukemia
. 2024 Jan;
38(3):630-639.
PMID: 38272991
Measurable residual disease (MRD) measured in the bone marrow (BM) of acute myeloid leukemia (AML) patients after induction chemotherapy is an established prognostic factor. Hemodilution, stemming from peripheral blood (PB)...